Medtronic Receives U.S. FDA Approval For New Neurostimulator With Innovative Patient Programmer
Feb 8th 2008Drug InformationPain / Anesthetics
Medtronic, Inc. (NYSE:MDT), announced it has received U.S. Food and Drug Administration (FDA) approval to market the RestoreULTRA? neurostimulation system for the treatment of chronic intractable pain of the trunk and/or limbs (chronic back and leg pain). This rechargeable neurostimulator, the most advanced device in the market-leading Medtronic family of RESTORE® devices, is the smallest and thinnest 16-electrode rechargeable neurostimulator available.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
